Avid Bioservices (NASDAQ:CDMO) released its quarterly earnings data on Monday. The biopharmaceutical company reported ($0.23) EPS for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.09), Bloomberg Earnings reports. Avid Bioservices had a negative return on equity of 52.55% and a negative net margin of 39.23%.
Shares of Avid Bioservices (NASDAQ CDMO) traded up $0.11 during trading hours on Monday, hitting $2.44. The company had a trading volume of 680,873 shares, compared to its average volume of 353,479. The stock has a market cap of $110.32, a P/E ratio of -3.49 and a beta of 2.43. Avid Bioservices has a 1-year low of $2.24 and a 1-year high of $5.78.
The business also recently announced a dividend, which will be paid on Monday, April 2nd. Investors of record on Monday, March 19th will be issued a dividend of $0.6563 per share. The ex-dividend date of this dividend is Friday, March 16th.
A number of equities analysts have recently commented on the company. Zacks Investment Research upgraded Avid Bioservices from a “sell” rating to a “hold” rating in a report on Tuesday, February 27th. Noble Financial restated a “buy” rating on shares of Avid Bioservices in a report on Friday, January 5th. Finally, ValuEngine downgraded Avid Bioservices from a “hold” rating to a “sell” rating in a report on Friday, December 1st.
ILLEGAL ACTIVITY NOTICE: This report was first published by Ticker Report and is owned by of Ticker Report. If you are viewing this report on another website, it was illegally stolen and republished in violation of U.S. and international copyright and trademark laws. The legal version of this report can be accessed at https://www.tickerreport.com/banking-finance/3258092/avid-bioservices-cdmo-releases-earnings-results-misses-estimates-by-0-09-eps.html.
Avid Bioservices Company Profile
Avid Bioservices, Inc, formerly Peregrine Pharmaceuticals, Inc, is a biopharmaceutical company. The Company is engaged in providing contract manufacturing services for third party customers on a fee-for-service basis while also supporting its internal drug development efforts. The Company delivers pharmaceutical products through its contract manufacturing business and through licensing its development-stage immunotherapy products.
Receive News & Ratings for Avid Bioservices Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Avid Bioservices and related companies with MarketBeat.com's FREE daily email newsletter.